glp-1 cardiovascular outcomes trial august 2025 outcome studies with receptor Results of cardiovascular outcomes trials

Most of them were mild to moderate in severity and improved over time

In contrast, products approved only for diabetes (Ozempic, Victoza, Mounjaro, Trulicity) generally do not contain these specific warnings

A fair better for weight loss conclusion If your primary goal is clinically meaningful weight loss and you meet medical criteria, semaglutide is typically the stronger option because it has stronger evidence and standardized prescribing/monitoring

Whilst weight reduction is often beneficial for patients with type 2 diabetes and overweight or obesity, excessive or rapid weight loss should be discussed with your healthcare provider

Daniel L

Kellar D, Lockhart SN, Aisen P, Raman R, Rissman RA, Brewer J, et al